View ValuationFarmacosmo 将来の成長Future 基準チェック /06現在、 Farmacosmoの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Specialty Retail 収益成長29.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • 8hFull year 2025 earnings releasedFull year 2025 results: Revenue: €56.3m (down 12% from FY 2024). Net loss: €4.43m (loss widened 49% from FY 2024).お知らせ • Jun 09Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026, at 08:00 W. Europe Standard Time.New Risk • May 24New major risk - Revenue and earnings growthEarnings have declined by 64% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€15.4m market cap, or US$17.9m).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Diego Rossano was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.お知らせ • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.お知らせ • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.New Risk • Oct 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €3.9m Forecast net loss in 2 years: €206k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€206k net loss in 2 years). Market cap is less than US$100m (€26.5m market cap, or US$29.4m).New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).New Risk • Apr 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$38.2m).New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$31.0m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.0m market cap, or US$42.1m).Board Change • Feb 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.お知らせ • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.お知らせ • Nov 13Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson.Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Farmacosmo S.p.A. (BIT:COSMO) completed the acquisition of a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022.お知らせ • Aug 10Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi.Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi on August 9, 2022.Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Farmacosmo は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:ZJ1 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202556-4-11N/A9/30/202558-5-3-1N/A6/30/202559-5-5-2N/A3/31/202562-4-4-2N/A12/31/202464-3-3-2N/A9/30/202466-3-2-1N/A6/30/202468-40-1N/A3/31/202470-4-3-3N/A12/31/202372-3-7-5N/A9/30/202372-2N/AN/AN/A6/30/202372-1N/AN/AN/A3/31/202369-1N/AN/AN/A12/31/202267-1N/AN/AN/A9/30/202266-1N/AN/AN/A6/30/2022640N/AN/AN/A3/31/2022610N/AN/AN/A12/31/2021580-10N/A9/30/2021561N/AN/AN/A12/31/202044012N/A12/31/2019240-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ZJ1の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ZJ1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ZJ1の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ZJ1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ZJ1の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ZJ1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YRetail 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 07:36終値2026/06/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Farmacosmo S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Filippo MazzoleniValueTrack
Reported Earnings • 8hFull year 2025 earnings releasedFull year 2025 results: Revenue: €56.3m (down 12% from FY 2024). Net loss: €4.43m (loss widened 49% from FY 2024).
お知らせ • Jun 09Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026Farmacosmo S.p.A., Annual General Meeting, Jun 22, 2026, at 08:00 W. Europe Standard Time.
New Risk • May 24New major risk - Revenue and earnings growthEarnings have declined by 64% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€15.4m market cap, or US$17.9m).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Diego Rossano was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 31Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million.Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi. The transaction is subject to approval of offer by target shareholders. illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being.
お知らせ • Dec 17Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million.Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl. The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority.
お知らせ • Apr 15Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time.
New Risk • Oct 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €3.9m Forecast net loss in 2 years: €206k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€206k net loss in 2 years). Market cap is less than US$100m (€26.5m market cap, or US$29.4m).
New Risk • May 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m).
New Risk • Apr 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$38.2m).
New Risk • Apr 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m).
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$31.0m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.0m market cap, or US$42.1m).
Board Change • Feb 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 04Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023.
お知らせ • Jan 10Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi.Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.
お知らせ • Nov 13Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson.Farmacosmo S.p.A. (BIT:COSMO) acquired a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022. Farmacosmo S.p.A. (BIT:COSMO) completed the acquisition of a 67% stake in Comprehensive Foot & Ankle Centers/Palmetto Podiatry Group of Anderson on November 11, 2022.
お知らせ • Aug 10Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi.Farmacosmo S.p.A. (BIT:COSMO) signed a binding agreement for the acquisition of 69.88% stake in VIN.CI. SRL from Vincenzo Cioffi on August 9, 2022.
Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.